A Phase 2 interventional study of 91-day Levonorgestrel Oral Contraceptive and 28-day Levonorgestrel Oral Contraceptive in Bone Mineral Density, sponsored by Duramed Research. Completed at 46 sites in United States. Open to female participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-22.
Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being conducted to compare the effects of a 91-day oral contraceptive (OC) to a 28-day OC regimen on bone mineral density (BMD) in adolescent females.
Participants will be randomized to either a 91-day OC or a 28-day OC. Participants not seeking hormonal contraception who meet eligibility criteria will serve as a control group. Duration of the study for each study participant will be approximately 13 months.
Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.
First submitted after Duramed Research became part of Teva Pharmaceutical Industries, Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
Drug: 91-day Levonorgestrel Oral Contraceptive
Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
Drug: 28-day Levonorgestrel Oral Contraceptive
Participants received no oral contraceptives during the study.
Drug pages: Levonorgestrel · Ethinyl Estradiol
Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet. Take 1 tablet daily
Also known as: levonorgestrel/ethinyl estradiol, DR-105, Seasonique®
Drug pages: Levonorgestrel · Ethinyl Estradiol
Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
Also known as: levonorgestrel/ethinyl estradiol, Lessina®
Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. Percent change from Baseline was calculated as (BMD at Month 12 - BMD at Baseline)/BMD at Baseline \* 100%.
Time frame: Baseline and Month 12
Change From Baseline in Lumbar Spine Bone Mineral Density
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)
Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Proximal Femur Bone Mineral Density
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Proximal Femur Bone Mineral Content (BMC)
Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Total Body Bone Mineral Density
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Total Body Bone Mineral Content (BMC)
Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Bone-specific Alkaline Phosphatase
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Serum Deoxypyridinoline
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Serum Osteocalcin
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Serum Procollagen 1 N-terminal Propeptide
Time frame: Baseline, Month 6 and Month 12
Change From Baseline in Serum Type I Collagen N-telopeptide
Time frame: Baseline, Month 6 and Month 12
Number of Participants With Adverse Events (AEs)
An adverse event was any untoward medical occurrence in a clinical investigation subject participating in the clinical study, and did not necessarily need to have a causal relationship with treatment or the clinical study. The relationship of each adverse event to study treatment or procedures, and the severity and seriousness of each adverse event was judged by the investigator, as described below. A severe AE is defined as incapacitating, with inability to perform usual activities. A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions: * fatal or life-threatening; * required or prolonged inpatient hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly or birth defect; * important medical event.
Time frame: 12 months
Healthy, postmenarcheal, adolescent females who were either willing to be randomly assigned to 1 of 2 open-label oral contraceptive (OC) treatment regimens or who were not seeking current treatment with hormonal contraceptives and agreed not to use hormonal contraception throughout the 12-month duration of the study (control group).
| Milestone | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Started | 458 | 448 | 455 |
| Received treatment | 422 | 411 | 0 |
| Completed | 247 | 240 | 372 |
| Not completed | 211 | 208 | 83 |
| Withdrew: Did not meet protocol requirements | 4 | 2 | 1 |
| Withdrew: Non compliance with the protocol | 20 | 15 | 4 |
| Withdrew: Physician decision | 2 | 3 | 4 |
| Withdrew: Withdrawal by subject | 50 | 44 | 18 |
| Withdrew: Adverse event | 39 | 33 | 0 |
| Withdrew: Pregnancy | 5 | 7 | 1 |
| Withdrew: Lost to follow-up | 78 | 94 | 45 |
| Withdrew: Miscellaneous reasons | 13 | 10 | 10 |
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists. Percent change from Baseline was calculated as (BMD at Month 12 - BMD at Baseline)/BMD at Baseline \* 100%.
| percent change | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD) | 2.26 ± 0.168 | 1.45 ± 0.171 | 2.50 ± 0.139 |
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.
| g/cm^2 | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 | 0.02 ± 0.001 | 0.01 ± 0.001 | 0.01 ± 0.001 |
| Change from Baseline to Month 12 | 0.02 ± 0.002 | 0.01 ± 0.002 | 0.03 ± 0.001 |
Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.
| g | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 | 1.29 ± 0.095 | 0.69 ± 0.097 | 1.12 ± 0.079 |
| Change from Baseline to Month 12 | 1.86 ± 0.120 | 1.20 ± 0.122 | 1.94 ± 0.099 |
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.
| g/cm^2 | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=238, 227, 358) | 0.01 ± 0.001 | 0.00 ± 0.001 | 0.01 ± 0.001 |
| Change from Baseline to Month 12 (n=238, 224, 359) | 0.02 ± 0.002 | 0.01 ± 0.002 | 0.01 ± 0.001 |
Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.
| g | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=238, 227, 358) | 0.26 ± 0.059 | 0.09 ± 0.061 | 0.13 ± 0.049 |
| Change from Baseline to Month 12 (n=238, 224, 359) | 0.59 ± 0.066 | 0.28 ± 0.068 | 0.43 ± 0.055 |
Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. DXA scans were interpreted centrally by blinded, certified technologists.
| g/cm^2 | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=130, 126, 149) | 0.01 ± 0.001 | 0.01 ± 0.001 | 0.01 ± 0.001 |
| Change from Baseline to Month 12 (n=130, 126, 150) | 0.01 ± 0.002 | 0.01 ± 0.002 | 0.02 ± 0.001 |
Bone mineral content was measured by dual energy X-ray absorptiometry (DXA) scans and interpreted centrally by blinded, certified technologists.
| g | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=130, 126, 149) | 40.77 ± 6.571 | 38.70 ± 6.638 | 46.26 ± 6.231 |
| Change from Baseline to Month 12 (n=130, 126, 150) | 72.86 ± 8.325 | 63.78 ± 8.409 | 84.95 ± 7.871 |
| µg/L | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=236, 224, 353) | -6.8 ± 8.31 | -5.9 ± 7.84 | -6.2 ± 10.42 |
| Change from Baseline to Month 12 (n=235, 225, 347) | -6.9 ± 8.64 | -6.6 ± 8.82 | -10.3 ± 12.49 |
| nmol/L | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=234, 224, 349) | -0.1 ± 2.43 | -0.1 ± 1.95 | 0.1 ± 2.33 |
| Change from Baseline to Month 12 (n=233, 226, 348) | -0.1 ± 2.21 | 0.1 ± 2.05 | -0.1 ± 2.28 |
| nmol/L | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=236, 224, 354) | -4.8 ± 7.00 | -3.9 ± 6.74 | -5.1 ± 11.94 |
| Change from Baseline to Month 12 (n=235, 225, 348) | -4.5 ± 6.69 | -3.7 ± 7.19 | -7.1 ± 11.74 |
| µg/L | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=237, 225, 355) | -49.9 ± 58.55 | -38.7 ± 51.14 | -57.8 ± 92.58 |
| Change from Baseline to Month 12 (n=235, 226, 349) | -50.4 ± 60.20 | -39.8 ± 55.73 | -86.0 ± 118.69 |
| nM bone collagen equivalents (BCE) | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Change from Baseline to Month 6 (n=235, 224, 356) | -4.8 ± 9.69 | -3.9 ± 10.68 | -0.7 ± 13.60 |
| Change from Baseline to Month 12 (n=236, 225, 350) | -4.5 ± 10.22 | -4.3 ± 10.71 | -3.1 ± 12.64 |
An adverse event was any untoward medical occurrence in a clinical investigation subject participating in the clinical study, and did not necessarily need to have a causal relationship with treatment or the clinical study. The relationship of each adverse event to study treatment or procedures, and the severity and seriousness of each adverse event was judged by the investigator, as described below. A severe AE is defined as incapacitating, with inability to perform usual activities. A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions: * fatal or life-threatening; * required or prolonged inpatient hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly or birth defect; * important medical event.
| participants | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| Any adverse event | 252 | 258 | 274 |
| Severe adverse event | 14 | 20 | 10 |
| Treat-related adverse event | 100 | 95 | 7 |
| Deaths | 0 | 0 | 0 |
| Other serious adverse events | 9 | 12 | 0 |
| Withdrawn from study due to adverse events | 34 | 33 | 1 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 91-day Levonorgestrel OC | — | 9/421 (2.1%) | 156/421 (37.1%) |
| 28-day Levonorgestrel OC | — | 12/412 (2.9%) | 160/412 (38.8%) |
| Untreated Control | — | 0/437 (0%) | 196/437 (44.9%) |
| Event | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| AppendicitisInfections and infestations | 2/421 | 1/412 | 0/437 |
| Wolff-Parkinson-White syndromeCardiac disorders | 0/421 | 1/412 | 0/437 |
| SerositisGeneral disorders | 0/421 | 1/412 | 0/437 |
| Clostridial infectionInfections and infestations | 0/421 | 1/412 | 0/437 |
| Post concussion syndromeInjury, poisoning and procedural complications | 0/421 | 1/412 | 0/437 |
| Knee deformityMusculoskeletal and connective tissue disorders | 0/421 | 1/412 | 0/437 |
| Abortion incompletePregnancy, puerperium and perinatal conditions | 0/421 | 1/412 | 0/437 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/421 | 1/412 | 0/437 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/421 | 1/412 | 0/437 |
| Affective disorderPsychiatric disorders | 0/421 | 1/412 | 0/437 |
| Event | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control |
|---|---|---|---|
| HeadacheNervous system disorders | 65/421 | 69/412 | 88/437 |
| NasopharyngitisInfections and infestations | 35/421 | 52/412 | 53/437 |
| Upper respiratory tract infectionInfections and infestations | 30/421 | 27/412 | 53/437 |
| DysmenorrhoeaReproductive system and breast disorders | 20/421 | 26/412 | 37/437 |
| MetrorrhagiaReproductive system and breast disorders | 29/421 | 14/412 | 0/437 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 14/421 | 10/412 | 30/437 |
| NauseaGastrointestinal disorders | 18/421 | 25/412 | 14/437 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/421 | 14/412 | 22/437 |
| Age, Continuous(years) | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control | Total |
|---|---|---|---|---|
| Mean | 16.0 ± 1.61 | 15.9 ± 1.71 | 14.8 ± 1.72 | 15.6 ± 1.77 |
| Sex: Female, Male(Participants) | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control | Total |
|---|---|---|---|---|
| Female | 458 | 448 | 455 | 1361 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | 91-day Levonorgestrel OC | 28-day Levonorgestrel OC | Untreated Control | Total |
|---|---|---|---|---|
| African-American | 87 | 87 | 72 | 246 |
| Asian | 3 | 9 | 12 | 24 |
| Caucasian | 251 | 265 | 255 | 771 |
| Hispanic | 102 | 79 | 111 | 292 |
| Other | 15 | 8 | 5 | 28 |
The record gives a start of Jun 2009, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 2 months after primary completion. A results delay was requested in Apr 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol